The Allergan Board Under Fire (A) Harvard Case Solution & Analysis

In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer along with a hedge fund activist, Pershing Square had quietly amassed a 9.7% stake in Allergan prior to the Valeant bid, making Pershing Square Allergan's largest stockholder.

The case presents pupils with several of the selections Allergan's directors faced amid challenges to Allergan's governance, management, and business model. In particular, the Allergan board must decide whether to pursue a $10 billion acquisition of Salix Pharmaceuticals while under threat of a proxy contest and also a special shareholder meeting to vote on replacing the directors using a slate of Allergan favorable to the Valeant merger. The projected Salix acquisition would give a new marketplace that is curative to Allergan but would also make Allergan too big for Valeant to obtain.

The Allergan Board Under Fire (A) case study solution

PUBLICATION DATE: January 04, 2016 PRODUCT #: 316010-HCB-ENG

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.